Thrombolytic therapy at systemic lupus onset with secondary antiphospholipid syndrome

References

1. ↵
   1. Mikdashi J,
   2. Handwerger B,
   3. Langenberg P,
   4. Miller M,
   5. Kittner S

   (2007) Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 38, 281–285.
2. ↵
   1. Nojima J,
   2. Kuratsune H,
   3. Suehisa E,
   4. Kitani T,
   5. Iwatani Y,
   6. Kanakura Y

   (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies--Co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91, 967–976.
3. ↵
   1. Schoenfeld SR,
   2. Kasturi S,
   3. Costenbader KH

   (2013) The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 43, 77–95.
4. ↵
   1. Petri M,
   2. Orbai AM,
   3. Alarcón GS,
   4. Gordon C,
   5. Merrill JT,
   6. Fortin PR,
   7. et al.

   (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64, 2677–2686.
5. ↵
   1. Kleindorfer D,
   2. Kissela B,
   3. Schneider A,
   4. Woo D,
   5. Khoury J,
   6. Miller R,
   7. Alwell K,
   8. et al.

   (2004) Eligibility for rtPA in acute ischemic stroke: a population-based study. Stroke 35, e27–e29.
6. ↵
   1. Mehta N,
   2. Uchino K,
   3. Fakhran S,
   4. Sattar MA,
   5. Branstetter BF 4th.,
   6. Au K,
   7. et al.

   (2008) Platelet C4d is associated with acute ischemic stroke and stroke severity. Stroke 39, 3236–3241.
7. ↵
   1. Bernatsky S,
   2. Clarke A,
   3. Gladman DD,
   4. Urowitz M,
   5. Fortin PR,
   6. Barr SG,
   7. Senécal JL,
   8. et al.

   (2006) Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus 15, 835–839.
8. ↵
   1. Janardhan V,
   2. Wolf PA,
   3. Kase CS,
   4. Massaro JM,
   5. D’Agostino RB,
   6. Franzblau C,
   7. et al.

   (2004) Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke 35, 736–741.
9. ↵
   (1995) Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333, 1581–1587.
10. ↵
    1. Hacke W,
    2. Kaste M,
    3. Bluhmki E,
    4. Brozman M,
    5. Dávalos A,
    6. Guidetti D,
    7. et al.

    (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359, 1317–1329.
11. ↵
    1. Saver JL,
    2. Fonarow GC,
    3. Smith EE,
    4. Reeves MJ,
    5. Grau-Sepulveda MV,
    6. Pan W,
    7. et al.

    (2013) Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 309, 2480–2488.
12. ↵
    1. Lees KR,
    2. Bluhmki E,
    3. von Kummer R,
    4. Brott TG,
    5. Toni D,
    6. Grotta JC,
    7. et al.

    (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375, 1695–1703.
13. ↵
    1. Rha JH,
    2. Saver JL

    (2007) The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 38, 967–973.
14. ↵
    1. Zangerle A,
    2. Kiechl S,
    3. Spiegel M,
    4. Furtner M,
    5. Knoflach M,
    6. Werner P,
    7. et al.

    (2007) Recanalization after thrombolysis in stroke patients: predictors and prognostic implications. Neurology 68, 39–44.
15. ↵
    1. Ribo M,
    2. Molina CA,
    3. Rovira A,
    4. Quintana M,
    5. Delgado P,
    6. Montaner J,
    7. et al.

    (2005) Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 36, 602–606.